Screener
Avalo Therapeutics AVTX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Avalo Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
FAQ
- What is Avalo Therapeutics's EBITDA margin?
- Avalo Therapeutics (AVTX) reported EBITDA margin of -15,497.7% in Q4 2024.
- How has Avalo Therapeutics's EBITDA margin changed year-over-year?
- Avalo Therapeutics's EBITDA margin decreased by 997.1% year-over-year, from -1,412.6% to -15,497.7%.
- What is the long-term trend for Avalo Therapeutics's EBITDA margin?
- Over 4 years (2020 to 2024), Avalo Therapeutics's EBITDA margin has grown at a 95.6% compound annual growth rate (CAGR), from -1,059.7% to -15,497.7%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Avalo Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude